Phase III EASE LID trial shows positive treatment effect in all age groups in levodopa-induced dyskinesia associated with Parkinson�s disease- Adamas Pharmaceuticals

Adamas Pharmaceuticals announced additional data from its Phase III clinical program of ADS-5102 (amantadine HCl) extended-release capsules for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson�s disease (PD). Analysis of data from EASE LID revealed a positive treatment effect for the ADS-5102-treated patients across all subgroups including: age, gender, renal function, and severity of motor complications (as measured at baseline).

As previously reported, the Phase III EASE LID study met its primary endpoint with a highly statistically significant reduction in dyskinesia at week 12. The study also met all five pre-specified key secondary endpoints. Improvement in LID was observed at the first post-baseline assessment at week 2 and durable throughout the study (week 24 observation). The efficacy of ADS-5102 was achieved without worsening the underlying PD.

ADS-5102 was generally well tolerated, and the types of adverse events (AEs) reported were consistent with the known safety profile of amantadine. Data were presented at the 20th Annual International Congress of Parkinson�s and Movement Disorders.